

DRAFT PROGRAMME FOR 2021 H3D SYMPOSIUM AS AT 28 APR 2020

Celebrating a Decade of Infectious Diseases Drug Discovery in Africa

Wednesday 10 March		
10h00 – 13h00	REGISTRATION	
SYMPOSIUM START		
THEME	<i>Global Health Perspective and Equity from Pharmaceutical Companies & Product Development Partnerships (CHAIR: TBD) 20 min talks</i>	
13h00 – 13h20	Speaker 1 – Kelly Chibale (H3D) – Welcome and introduction	
13h20 – 13h40	Speaker 2 - Guilherme Cintra (IFPMA)	Strengthening networks to foster NTD research – lessons learned from WIPO Re:Search
13h40 – 14h00	Speaker 3 - Manica Balasegaram (GARDP)	
14h00 – 14h20	Speaker 4 - Lutz Hegemann (Novartis)	
14h20 – 14h40	Speaker 5 – Fabian Gusovsky (EISAI)	
14h40 – 15h00	Speaker 6 - Intro Sci Speaker – Dennis Smith	Predicting Human Dose during the Discovery Stage
15h00 – 15h20	Speaker 7 – Bernhards Ogutu (KEMRI)	
15h20 - 16h00	<i>TEA / COFFEE BREAK / Accommodations</i>	
THEME	<i>Neglected Tropical Diseases (CHAIR: TBD) 25 min talk 5 min Q</i>	
16h00 – 16h30	NTD Speaker 1 – James Collins (Univ. Texas SWMC)	Sex, drugs, and snails: a deeper molecular understanding of schistosome biology
16h30 – 17h00	NTD Speaker 2 – Jennifer Keiser (STPH)	Advances to treat helminth infections: from bench to communities

17h00 – 17h30	NTD Speaker 3 – Paul Wyatt (DDU)	The Development of DDD1305143; A Preclinical Candidate for the Treatment of Visceral Leishmaniasis
19h30 – 21h30	<i>COCKTAIL PARTY</i>	
Thursday 11 March		
THEME	<i>Malaria (CHAIR: TBD) 25 min talk 5 min Q</i>	
08h30 – 09h00	Malaria Speaker 1 – Jeremy Burrows (MMV)	Progress and challenges towards discovering the next generation of antimalarials
09h00 – 09h30	Malaria Speaker 2 – Lyn-Marie Birkholtz (Univ. Pretoria)	Transmission-blocking antimalarials: a tool to elimination?
09h30 – 09h50	Short Orals 1 & 2	
09h50 – 10h20	Malaria Speaker 3 – David Fidock (Columbia Univ.)	
10h20 – 10h50	<i>TEA /COFFEE BREAK</i>	
10h50 – 11h20	Malaria Speaker 4 – Thomas Spangenberg (Merck)	Preclinical Antimalarial Studies: The Case of M5717, a P. falciparum Elongation Factor 2 Inhibitor
11h20 – 11h40	Short Orals 3 & 4	
11h40 – 12h10	Malaria Speaker 5 – Sergio Wittlin (STPH)	With H3D you never fly alone
12h10 – 12h30	Short Orals 5 & 6	
12h30 – 13h00	Malaria Speaker 6 – Leann Tilley (Univ. Melbourne)	Targeting proteostasis for antimalarial drug development
13h00 – 14h30	<i>LUNCH BREAK</i>	
THEME	<i>AMR (CHAIR: TBD) 25 min talk 5 min Q</i>	
14h30 – 15h00	AMR Speaker 1 – Adrian Brink (Univ. of Cape Town)	Epidemiology of MDR Gram-negative infections: Determinants influencing future dissemination and control

15h00 – 15h20	Short Oral Slots – 7 & 8	
15h20 – 15h50	AMR Speaker 2 – Colin Fishwick (Leeds Univ.)	
15h50 – 16h30	TEA /COFFEE BREAK	
16h30 - 18h00	POSTERS 21- 40	
19h30 – 22h00	CONFERENCE DINNER	
Friday 12 March		
THEME	<i>Tuberculosis (CHAIR: TBD) 25 min talk 5 min Q</i>	
08h30 – 09h00	TB Speaker 1 – Andreas Diacon (Univ. Stellenbosch)	Novel Antituberculosis Agents
09h00 – 09h30	TB Speaker 2 – Mary Jackson (Colorado State Univ.)	Mycolic acid biosynthesis in Mycobacterium tuberculosis: Old target, new drugs.
09h30 – 10h00	TB Speaker 3 – Tanya Parish (Seattle Children’s Res. Inst.)	Ten years of anti-tubercular screening - how have we improved
10h00 – 10h30	TEA / COFFEE BREAK	
THEME	TB Cont’d (CHAIR: TBD)	
10h30 – 11h00	TB Speaker 4 – Neil Osheroff (Vanderbilt Univ.)	Re-targeting Gyrase: the Quest to Overcome Fluoroquinolone Resistance in Tuberculosis
11h00 – 11h20	Short Orals 9 & 10	
11h20 – 11h40	TB Speaker 5 – Clif Barry (NIH NIAID)	
11h40 – 13h00	LUNCH BREAK	
13h00 – 13h30	TB Speaker 6 – Brendan Crowley (Merck USA)	Next Generation Oxazolidinone Antibiotics for the Treatment of Tuberculosis

13h30 – 14h00	TB Speaker 7– Dirk Schnappinger (Weill Cornell)	In vivo and in vitro gene essentiality of Mycobacterium tuberculosis
14h00 – 14h30	TB Speaker 8 - Peter Warner (BMGF)	Opportunities and Challenges in Global Health Drug Discovery
14h30 – 14h45	Closing Remarks: Kelly Chibale (Director, H3D)	
14h45 - 15h30	<i>TEA / COFFEE/GOODBYE'S</i>	